查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918124

伽玛刀市场－2026-2031年预测

Gamma Knife Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计伽玛刀市场将从 2025 年的 422,965,000 美元增长到 2031 年的 571,712,000 美元，复合年增长率为 5.15%。

伽玛刀市场：产业分析

伽玛刀市场正以 5.15% 的强劲复合年增长率成长，预计到 2031 年将达到 571,712,000 美元。这种专为脑肿瘤和神经系统疾病的非侵入性放射外科手术而设计的专用医疗设备，在全球医疗保健系统中日益受到重视，因为这些系统正在寻求针对复杂神经系统疾病的精准且微创的治疗方法方案。

市场驱动因素

脑肿瘤的盛行率

脑肿瘤发生率的不断上升是伽玛刀市场扩张的主要驱动力。该设备的高精度引导系统和专用准直器能够将多束放射线精确地聚焦于目标病灶，从而在有效治疗的同时，最大限度地减少对健康脑组织的辐射暴露。这种精准性尤其重要，因为脑肿瘤是所有癌症中存活期最短的，平均存活期仅27年。这项能够以亚毫米级精度标靶肿瘤的技术，正日益成为神经外科医师和放射肿瘤科医师治疗这些疑难病例的首选。

应用于神经系统疾病

除了脑肿瘤，伽玛刀放射手术在多种神经系统疾病中也展现出疗效，拓展了其临床效用。该技术透过将辐射聚焦于异常血管来治疗某些动静脉畸形，使其逐渐闭合。此外，伽玛刀在运动障碍（包括自发性震颤和帕金森氏症）治疗方面的潜在应用也正在研究中。在美国，约有4,200万人受运动障碍影响，因此，治疗范围的扩大显着提升了市场潜力，并将伽玛刀技术定位为治疗神经系统疾病的多功能工具。

诊断影像软体集成

影像软体的进步在提升伽玛刀治疗计划和实施方面发挥关键作用。现代影像平台能够精确勾勒出标靶病灶，确保手术过程中标靶的准确定位。三维成像功能结合专用演算法和先进工具，有助于制定优化的治疗计划，最大限度地提高病灶组织的辐射剂量，同时最大限度地减少对周围正常组织的辐射暴露。这些技术进步有助于持续改善治疗效果，并扩大伽玛刀放射放射线手术的适用临床范围。

人口结构方面的必然要求

人口老化是脑肿瘤和神经系统疾病发生率上升的关键驱动因素。世界正经历显着的人口结构变化，预计60岁及以上人口的比例将从2015年的12%增加到2050年的22%。此外，预计60岁及以上人口将从2020年的10亿增加到2031年的14亿。这些人口结构变化使得人们对伽玛刀技术所提供的有效、微创治疗方案的需求持续成长。

教育活动

随着患者和医护人员对伽玛刀放射放射线手术益处的认识不断提高，其应用普及率正在加速成长。教育活动、线上资源和资讯共用平台正在加深人们对这项技术的功能和临床应用的理解。专门的培训课程应运而生，旨在支持医护人员的培养，确保伽玛刀系统的正确使用，从而促进其在医疗机构中更广泛的应用。

市场限制

儘管伽玛刀市场呈现良好的成长趋势，但仍面临诸多挑战。伽玛刀系统的复杂性和专业性意味着高昂的成本，这可能会阻碍其普及应用。医疗机构必须克服巨额的初始资本投资以及持续的维护和营运成本，这可能成为推广应用的障碍，尤其对于资金预算有限的机构。此外，成功实施伽玛刀技术需要专用设备和合格的医务人员，这可能会限制其在某些地区和医疗机构（例如资源和训练有素的专业人员有限的发展中地区）的普及应用。

区域趋势

预计北美在预测期内将保持显着的市场份额。这一区域主导地位可归因于以下几个因素：脑肿瘤发生率上升、医疗基础设施完善、研究活动活跃、宣传教育覆盖面广以及老年人口不断增长。预计2023年将新增约25,000例恶性脑或脊髓肿瘤病例。该地区60岁及以上人口预计将从2019年的5,410万增至2040年的8,080万，将进一步推动区域市场成长，因为该年龄层罹患脑肿瘤的风险更高。

在技​​术进步、人口结构变化和临床应用不断拓展的推动下，伽玛刀市场持续发展。随着医疗系统优先考虑针对复杂神经系统疾病的精准、非侵入性治疗方法，这些因素将推动市场持续成长。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 按疾病分類的伽玛刀市场

  • 介绍
  • 脑转移
  • 癌症
  • 动静脉畸形
  • 三叉神经痛
  • 其他的

6. 按解剖部位分類的伽玛刀市场

  • 介绍
  • 头
  • 脖子
  • 其他的

7. 伽玛刀市场依分销管道划分

  • 介绍
  • 在线的
  • 离线

8. 伽玛刀市场区域划分

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Elekta
  • Bionity
  • Mayo Clinic
  • Beaumont Health
  • Intermountain Healthcare
  • Karolinska
  • Allina Health
  • Riverside Health Systems
  • Varian Medical Systems
  • Akesis Inc.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615914

The gamma knife market, with a 5.15% CAGR, is anticipated to rise from USD 422.965 million in 2025 to USD 571.712 million in 2031.

Gamma Knife Market: Industry Analysis

The Gamma Knife market is experiencing robust growth at a 5.15% CAGR, projected to reach USD 571.712 million in 2031. This specialized medical device, designed for non-invasive radiosurgery targeting brain tumors and neurological conditions, is gaining prominence as healthcare systems worldwide seek precise, minimally invasive treatment alternatives for complex neurological pathologies.

Fundamental Market Drivers

Brain Tumor Prevalence

The increasing incidence of brain tumors represents a primary catalyst for Gamma Knife market expansion. The device's highly accurate guidance system and specialized collimators enable precise focusing of multiple radiation beams on target lesions, delivering effective treatment while minimizing radiation exposure to healthy brain tissue. This precision is particularly critical given that brain tumors significantly impact life expectancy, reducing it by an average of 27 years-the highest reduction among all cancer types. The technology's ability to target tumors with submillimeter accuracy makes it an increasingly preferred option for neurosurgeons and radiation oncologists managing these challenging cases.

Neurological Disorder Applications

Beyond brain tumors, Gamma Knife radiosurgery has demonstrated effectiveness across various neurological conditions, broadening its clinical utility. The technology treats selected arteriovenous malformations by focusing radiation on aberrant vessels, causing progressive closure over time. Additionally, research has explored Gamma Knife applications for movement disorders including essential tremors and Parkinson's disease. With approximately 42 million people in the U.S. population affected by movement disorders, this expanded therapeutic scope significantly amplifies market potential and positions Gamma Knife technology as a versatile tool in the neurological treatment armamentarium.

Imaging Software Integration

Advancements in imaging software have become instrumental in enhancing Gamma Knife treatment planning and execution. Modern imaging platforms enable precise delineation of target lesions, ensuring accurate targeting during procedures. Three-dimensional imaging capabilities, combined with specialized algorithms and sophisticated tools, facilitate creation of optimized treatment plans that maximize radiation delivery to pathological tissue while minimizing exposure to surrounding healthy structures. These technological refinements continue improving treatment outcomes and expanding the clinical scenarios where Gamma Knife radiosurgery represents a viable option.

Demographic Imperatives

The growing geriatric population constitutes a significant driver, as aging populations experience higher prevalence of brain tumors and neurological conditions. The global demographic shift is substantial: the proportion of people aged over 60 years worldwide is projected to increase from 12% to 22% between 2015 and 2050. Furthermore, the absolute number of individuals aged 60 years or above is estimated to grow from 1 billion in 2020 to 1.4 billion by 2031. This demographic evolution creates sustained demand for effective, minimally invasive treatment solutions that Gamma Knife technology provides.

Educational Initiatives

Increasing awareness among patients and healthcare professionals regarding Gamma Knife radiosurgery benefits is accelerating adoption rates. Educational initiatives, online resources, and information-sharing platforms have enhanced understanding of the technology's capabilities and clinical applications. Specialized training programs have emerged to support workforce development and ensure proper utilization of Gamma Knife systems, facilitating broader implementation across healthcare institutions.

Market Constraints

Despite positive growth trajectories, the Gamma Knife market faces notable challenges. The complexity and specialization of Gamma Knife systems translate to substantial costs that may impede adoption. Healthcare institutions must navigate significant initial equipment investments alongside ongoing maintenance and operational expenses, which can present barriers to integration, particularly for facilities with constrained capital budgets. Additionally, successful implementation requires specialized equipment and qualified medical personnel, potentially limiting availability in certain geographic areas or healthcare settings, especially in developing regions with limited resources or trained specialists.

Regional Dynamics

North America is positioned to maintain a significant market share during the forecast period. This regional strength stems from multiple factors: rising brain tumor incidence, robust healthcare infrastructure, active research initiatives, comprehensive awareness programs, and an expanding elderly population. Projections indicate approximately 25,000 new cases of malignant brain or spinal cord tumors in 2023. The region's population aged 60 years or above is projected to reach 80.8 million by 2040, up from 54.1 million in 2019, with this demographic showing elevated brain cancer risk, further supporting regional market growth.

The Gamma Knife market continues evolving, propelled by technological advancement, demographic shifts, and expanding clinical applications. These converging factors position the market for sustained growth as healthcare systems prioritize precise, non-invasive treatment modalities for complex neurological conditions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Gamma Knife Market Segmentation

  • By Disease
  • Brain Metastasis
  • Cancer
  • Arteriovenous Malformation
  • Trigeminal Neuralgia
  • Others
  • By Anatomy
  • Head
  • Neck
  • Others
  • By Distribution Channel
  • Online
  • Offline
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GAMMA KNIFE MARKET BY DISEASE

  • 5.1. Introduction
  • 5.2. Brain Metastasis
  • 5.3. Cancer
  • 5.4. Arteriovenous Malformation
  • 5.5. Trigeminal Neuralgia
  • 5.6. Others

6. GAMMA KNIFE MARKET BY ANATOMY

  • 6.1. Introduction
  • 6.2. Head
  • 6.3. Neck
  • 6.4. Others

7. GAMMA KNIFE MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Online
  • 7.3. Offline

8. GAMMA KNIFE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Elekta
  • 10.2. Bionity
  • 10.3. Mayo Clinic
  • 10.4. Beaumont Health
  • 10.5. Intermountain Healthcare
  • 10.6. Karolinska
  • 10.7. Allina Health
  • 10.8. Riverside Health Systems
  • 10.9. Varian Medical Systems
  • 10.10. Akesis Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations